Home / 2019 / February / 01

Daily Archives: February 1, 2019

Kofax Announces the Closing of its Acquisition of Nuance Document Imaging

Acquisition Extends Kofax Leadership in Cognitive Capture by Securing Innovative Technologies to Enhance its Intelligent Automation Platform

IRVINE, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) — Kofax®, a leading supplier of Intelligent Automation software to automate and digitally transform end-to-end business processes, today announced the closing of its acquisition of Nuance Document Imaging (NDI), a division of Nuance Communications, Inc. (NASDAQ: NUAN).

NDI provides software to help organizations optimize their information-based capture and print processes from being labor intensive, error prone and costly, into becoming highly efficient, automated and secure.

Through this acquisition, Kofax is driving customer value by adding key technologies, including capture, print management and document security on MFPs, to its end-to-end Intelligent Automation platform.

About Kofax

Kofax software enables organizations to Work Like Tomorrow™–today. Kofax’s Intelligent Automation software platform helps organizations transform information-intensive business processes, reduce manual work and errors, minimize costs, and improve customer engagement. We combine RPA, cognitive capture, process orchestration, mobility and engagement, and analytics to ease implementations and deliver dramatic results that mitigate compliance risk and increase competitiveness, growth and profitability. Kofax provides a rapid return on investment for over 20,000 customers in financial services, insurance, government, healthcare, supply chain, business process outsourcing and other markets. Kofax delivers its software and solutions through its direct sales and services organization and more than 650 indirect channel partners and integrators in more than 60 countries throughout the Americas, EMEA and Asia Pacific. For more information, visit kofax.com.

© 2019 Kofax, Inc. Kofax is a registered trademark of Kofax Limited.

Source: KOFAX

Media Contact:
Amanda Ingalls
Public Relations Director
+1 (949) 783-1595
Amanda.Ingalls@kofax.com

Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Zug, Switzerland, 1 February 2019: Lupin is pleased to announce that NaMuscla® (mexiletine) has been launched in Germany and the United Kingdom (UK). NaMuscla® is approved across the European Union (EU) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. These disorders are a group of rare, inherited neuromuscular conditions in which myotonia, the inability to relax muscles following voluntary contraction, is the most prominent clinical symptom. NaMuscla® reduces myotonia symptoms in adult patients, resulting in a significant improvement in patient quality-of-life and other functional outcomes1,5.

The launch of NaMuscla® in Germany and the UK follows the European Commission’s approval of the product on 18 December 2018. NaMuscla®, designated an Orphan Drug by the European Medicines Agency (EMA), is the first treatment to be licensed across the EU for the symptomatic treatment of myotonia in adults with NDM disorders. The product will be commercialized in Germany by Hormosan Pharma GmbH, a full subsidiary of Lupin Ltd., and in the UK by Lupin Healthcare (UK) Ltd.

“We are delighted to be able to provide patient and market access to NaMuscla® in Germany and the UK,” said Thierry Volle, President EMEA, Lupin. “NaMuscla® is the first licensed therapy for myotonia across the EU and offers an effective treatment option for patients living with this life-altering symptom. We look forward to additional launches for patients in other EU territories through 2019 and 2020.”

Lupin has ongoing partnering discussions for the commercialization of NaMuscla® in European territories outside of Germany and the UK.

Prior to the approval of NaMuscla®, the vast majority of more than 7500 people in Europe2,3,4 living with NDM had limited access to a licensed treatment for myotonia which reduced the daily burden of this life-altering symptom. Limited access leads to inconsistent medication supply, administrative challenges to both treating physicians and patients and associated financial burdens; this, along with low awareness and clinical experience among healthcare professionals, can result in harm to patients4. The EMA recognized the importance of having an effective therapy in adult NDM patients throughout the EU by granting NaMuscla® Orphan Drug status and the corresponding market exclusivity protection.

For further information or queries please contact:

Consilium Strategic Communications
Amber Fennell / Julia Wilson/ Sukaina Virji/ Angela Gray
Tel: +44 (0)20 3709 5700
Email: lupin@consilium-comms.com

Notes for Editors

About Myotonic Disorders and Non-Dystrophic Myotonic (NDM) Disorders
Myotonic disorders are a group of heterogeneous, inherited, neuromuscular disorders characterized by a shared symptom called myotonia. Myotonia can be described as an inability to relax a contraction of skeletal muscle which originates from a voluntary muscular contraction such as shaking someone’s hand and blinking, or everyday activities such as walking across a street and climbing stairs.

Non-dystrophic myotonias (NDM) are a sub-set of rare (prevalence of 1:100,0006), inherited, myotonic disorders which are caused by mutations within ion channels in the sarcolemma membrane of skeletal muscles. Non-dystrophic myotonias exhibit both sodium and chloride channelopathies which result in altered membrane excitability. For patients with NDM, myotonia is the most prominent symptom and demonstrates different phenotypes in subgroups of NDM disorders, and can affect different parts of the body, such as legs, arms or facial muscles, more severely. Myotonia in NDM patients has an onset in childhood and persists over the patient’s lifetime – significantly impacting the patient’s daily life. Myotonia is described by patients in a variety of ways (stiffness, cramps, pain, difficulty releasing a fist, or difficulty swallowing or eating) which can contribute to substantial delays in diagnosis and treatment, leading to decreased patient quality-of-life and often significant disability.

About NaMuscla® (mexiletine)
NaMuscla® is an antimyotonic agent licensed to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders. In randomized controlled trials, NaMuscla® (167 to 500 mg mexiletine/day) has been shown to significantly reduce myotonia compared to placebo, restoring skeletal muscle hyperexcitability through its use-dependent, voltage-gated, sodium channel-blocking actions which are independent of the cause of channel function. This resulted in an improvement in patient quality-of-life and other functional outcomes, with gastro-intestinal discomfort reported as the most common adverse event, demonstrating NaMuscla® to be safe and generally well tolerated1,5.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 13th largest generics pharmaceutical company in terms of market capitalization (30th September 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th June 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3rd largest Indian pharmaceutical company by global revenues (30th June 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).

For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

Sundance Energy Provides January 2019 Operational Update

DENVER, Jan. 31, 2019 (GLOBE NEWSWIRE) — Sundance Energy Australia Limited (ASX: SEA) (NASDAQ: SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas is pleased to announce that it exceeded its production guidance for full year 2018 and met its production guidance for fourth quarter 2018. The Company’s full year 2018 net production averaged approximately 10,000 Boe/d including flared volumes, at the top end of full year net production guidance of 9,000 to 10,000 Boe/d. During the fourth quarter of 2018, the Company produced approximately 14,000 Boe/d including flared volumes, meeting fourth quarter production guidance of 14,000 to 15,000 Boe/d.

The Company’s cumulative net production for the fourth quarter was approximately 1,300,000 Boe. Net production comprised approximately 900,000 barrels of oil, 150,000 barrels of natural gas liquids and 1,700,000 thousand cubic feet of natural gas. Production for the period was ~68% oil by volume.

The Company’s cumulative net production for full year 2018 was approximately 3,700,000 Boe. Net production comprised approximately 2,300,000 barrels of oil, 490,000 barrels of natural gas liquids and 5,700,000 thousand cubic feet of natural gas. Production for the year was ~61% oil by volume.

Due to better than expected well performance, the Company’s higher production volumes have resulted in increased line pressure and capacity constraints at a third-party gas processing facility earlier than planned. The Company expects the issue to be resolved in the first half of the year through a facility expansion. In the meantime, the Company has been appropriately managing production volumes and flaring additional gas volumes.

Development Activities

Sundance brought 11 gross (11 net) wells onto production during the fourth quarter, bringing the total number of gross wells brought online in 2018 to 23 (23 net).

During the fourth quarter, Sundance brought onto production 9 gross (9 net) wells on the acreage acquired from Pioneer in Live Oak County. Initial production results from all wells were significantly above the Company’s well performance expectations, and all wells continue to perform above type curve. Sundance additionally brought online two gross (two net) wells on its legacy acreage in McMullen County.

Additionally, during the fourth quarter the Company completed drilling (“SPUD to TD”) on two additional gross (two net) wells in Dimmit County with a subsequently released spot rig and at quarter’s end was in the process of drilling the Roy Esse 15H, 16H, 17H and 18H four well pad in Live Oak County.

As of the date of this report, the Company has finished drilling the Roy Esse pad and is in the process of drilling the Bracken 23H and 24H two well pad in McMullen County. During January the Company fracked the Red Ranch 18H and 19H two well pad in Dimmit County and has initiated flow back on the pad.

The Company delayed picking up a second rig in the fourth quarter of 2018 in response to weaker commodity prices, and has additionally elected to scale back first quarter 2019 development plans. During the first quarter 2019 the Company intends to drill 6 wells and complete four wells.

Financial Disclosures

Upon conclusion of its annual audit in March 2019, the Company will provide full fourth quarter financial results as well as audited financial statements for the 2018 fiscal year including a Statement of Operations, Consolidated Balance Sheet, and Statement of Cash Flows. The Company will also provide an Adjusted EBITDA reconciliation at that time.

Exhibit A: Fourth Quarter Initial Well Results

Well Name County IP Date Completed
Lat Length
30-Day IP
(boepd)
30-Day /
1,000′ ft
60-Day IP
(boepd)
60-Day /
1,000′ ft
% Oil
Idylwood 04H Live Oak 16-Oct 6,445   1,021   158   1,079   167 83 %
Idylwood 05H Live Oak 16-Oct 5,487   1,171   213   1,152   210 81 %
James Keith Esse 06H Live Oak 13-Nov 5,175   1,212   234   1,222   236 74 %
James Keith Esse 07H Live Oak 13-Nov 5,178   923   178   966   187 75 %
James Keith Esse 08H Live Oak 13-Nov 5,180   1,119   216   1,148   222 75 %
James Keith Esse 09H Live Oak 13-Nov 5,164   1,333   258   1,291   250 73 %
Hoskins 20H McMullen 2-Dec 7,266   561   77  –  – 86 %
Hoskins 21H McMullen 2-Dec 7,116   909   128  –  – 82 %
Harlan Bethune 22H Live Oak 15-Dec 5,301  –  –  –  –
Harlan Bethune 23H Live Oak 15-Dec 5,621   1,330   237  –  – 79 %
Harlan Bethune 24H Live Oak 15-Dec 5,737  –  –  –  –

 Exhibit B: Full Year 2018 Activities Overview 

Well Name County Spud
Date
Frac Start
Date
IP
Date
Lateral
Length
30-Day IP (boe/d) 60-Day IP (boe/d) 90-Day IP (boe/d)
Paloma Ranch 7H McMullen 18-Jan-18 17-May-18 2-Jun-18 7,690′   1,345 1,017   811
Peeler Ranch 8HC Atascosa 1-Mar-18 28-May-18 26-Jun-18 5,642′   484 404   367
Peeler Ranch 9HC Atascosa 24-Mar-18 28-May-18 26-Jun-18 5,820′   446 371   314
Allen MCM 1HA McMullen 21-Apr-18 6-Jul-18 17-Aug-18 8,015′   1,291 1,100   942
Allen MCM 2HA McMullen 13-May-18 6-Jul-18 17-Aug-18 8,234′   1,132 969   843
Harlan Bethune 25H Live Oak 7-May-18 24-Jul-18 15-Aug-18 4,779′   1,102 1,091   974
Harlan Bethune 26H Live Oak 11-May-18 22-Jul-18 15-Aug-18 4,073′   1,234 1,066   920
Harlan Bethune 27H Live Oak 13-May-18 22-Jul-18 15-Aug-18 3,314′   1,183 901   750
Justin Tom 05H Atascosa 17-Jun-18 12-Aug-18 3-Sep-18 6,258′   1,296 1,146 1,003
Justin Tom 06H Atascosa 14-Jun-18 12-Aug-18 3-Sep-18 6,299′   1,042 826 834
Harlan Bethune 34H Live Oak 25-Jun-18 3-Aug-18 19-Aug-18 3,528′   1,691 1,588   1,344
Harlan Bethune 35H Live Oak 22-Jun-18 3-Aug-18 19-Aug-18 3,702′   1,738 1,579   1,321
James Keith Esse 06H Live Oak 26-Jul-18 12-Oct-18 13-Nov-18 5,175′ 1,212 1,222
James Keith Esse 07H Live Oak 22-Jul-18 12-Oct-18 13-Nov-18 5,178′ 923 966
James Keith Esse 08H Live Oak 24-Jul-18 12-Oct-18 13-Nov-18 5,180′ 1,119 1,148
James Keith Esse 09H Live Oak 20-Jul-18 12-Oct-18 13-Nov-18 5,164′ 1,333 1,291
Idylwood 04H Live Oak 3-Aug-18 28-Sep-18 16-Oct-18 6,445′   1,021   1,079
Idylwood 05H Live Oak 3-Aug-18 28-Sep-18 16-Oct-18 5,487′   1,171   1,152
Harlan Bethune 22H Live Oak 17-Sep-18 27-Nov-18 15-Dec-18 5,301′
Harlan Bethune 23H Live Oak 21-Sep-18 27-Nov-18 15-Dec-18 5,621′ 1,330
Harlan Bethune 24H Live Oak 25-Sep-18 27-Nov-18 15-Dec-18 5,737′
Hoskins 20H McMullen 25-Sep-18 9-Nov-18 2-Dec-18 7,266′ 561
Hoskins 21H McMullen 27-Sep-18 9-Nov-18 2-Dec-18 7,116′   909
Roy Esse 15H Live Oak 1-Dec-18
Roy Esse 16H Live Oak 28-Nov-18
Roy Esse 17H Live Oak 26-Nov-18
Roy Esse 18H Live Oak 24-Nov-18
Red Ranch 18H Dimmit 20-Nov-18 8-Jan-19
Red Ranch 19H Dimmit 19-Nov-18 8-Jan-19

 

For more information, please contact:
United States:
John Roberts
VP Finance & Investor Relations
Tel: +1 (720) 638-2400
Eric McCrady
CEO and Managing Director
Tel: +1 (303) 543-5703
Australia:
Mike Hannell
Chairman
Tel: +61 8 8363 0388

About Sundance Energy Australia Limited
Sundance Energy Australia Limited (“Sundance” or the “Company”) is an Australian-based, independent energy exploration company, with a wholly owned US subsidiary, Sundance Energy Inc., located in Denver, Colorado, USA. The Company is focused on the acquisition and development of large, repeatable oil and natural gas resource plays in North America. Current activities are focused in the Eagle Ford.  A comprehensive overview of the Company can be found on Sundance’s website at www.sundanceenergy.net

Summary Information
The following disclaimer applies to this document and any information contained in it. The information in this release is of general background and does not purport to be complete. It should be read in conjunction with Sundance’s periodic and continuous disclosure announcements lodged with ASX Limited that are available at www.asx.com.au and Sundance’s filings with the Securities and Exchange Commission available at www.sec.gov.  

Forward Looking Statements
This release may contain forward-looking statements. These statements relate to the Company’s expectations, beliefs, intentions or strategies regarding the future. These statements can be identified by the use of words like “anticipate”, “believe”, “intend”, “estimate”, “expect”, “may”, “plan”, “project”, “will”, “should”, “seek” and similar words or expressions containing same.

These forward-looking statements reflect the Company’s views and assumptions with respect to future events as of the date of this release and are subject to a variety of unpredictable risks, uncertainties, and other unknowns. Actual and future results and trends could differ materially from those set forth in such statements due to various factors, many of which are beyond our ability to control or predict. These include, but are not limited to, risks or uncertainties associated with the discovery and development of oil and natural gas reserves, cash flows and liquidity, business and financial strategy, budget, projections and operating results, oil and natural gas prices, amount, nature and timing of capital expenditures, including future development costs, availability and terms of capital and general economic and business conditions. Given these uncertainties, no one should place undue reliance on any forward looking statements attributable to Sundance, or any of its affiliates or persons acting on its behalf.  Although every effort has been made to ensure this release sets forth a fair and accurate view, we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

1Masjid 1Polis will be implemented nationwide in March – JPJKK director

KUALA LUMPUR— The 1Masjid 1Polis (1M1P) programme will be expanded throughout the country starting March in order to curb crimes and to ensure safety around mosques, according to police.

To date, 6,047 mosques registered under Terengganu and Pahang Islamic Religious Councils had implemented the programme since 2012.

Bukit Aman Crime Prevention and Community Safety Department (JPJKK) director Datuk Seri Rosli Ab Rahman said the department would appoint a liaison officer in each mosque and provide a police patrol box to highlight the presence of police.

Source: Bernama

DPM: just one young offender still detained under POCA

KUALA LUMPUR– Just one young offender is still being detained under the Criminal Prevention Act 1959 (POCA) for armed robbery.

Deputy Prime Minister, Datuk Seri Dr Wan Azizah Wan Ismail, said the person is currently at a detention centre for two years and away from adult detainees in the Kluang Special Rehabilitation Centre in Johor.

She was responding to a news report yesterday where Suara Rakyat Malaysia (Suaram) and the Human Rights Commission of Malaysia (Suhakam) urged the government to release 142 young offenders still being detained under POCA because it is harmful to children.

She said to reporters today: “I felt shocked at the revelation, so I immediately called the minister and also the ministry in charge the police told us that actually only one is left under POCA up till Jan 30.”

Dr Wan Azizah, who is also the Women, Family and Community Development minister, was at the Taman Muda market and Pandan Perdana morning market distributing mandarin oranges.

Asked if it is just for juveniles detained under POCA to be released, she said it was something that has to be looked into by the police and appropriate ministries.

According to statistics by the Ministry of Home Affairs, 27 young offenders are currently under observation for two years by the police for being involved in criminal organisations, robbery, motorcycle theft and so on.

Regarding the electronic monitoring device (EMD) being worn by young offenders, she said only those ascertained to have committed a grave crime by the Violence and Crime Prevention Board are using it.

While Dr Wan Azizah did not disclose how many are being monitored this way, she said discussions will be held with the Home Affairs Ministry on the juvenile detention system.

Although the young offender is not being kept in custody alongside adults, we should have a relook to ensure that it doesn’t happen at all.

We have to look into it because no child should be exposed to this sort of environment I think for those under 18, we should review the matter deeply, she said.

At the same time, Dr Wan Azizah was asked by reporters on the coalition’s progress in picking a candidate for the Semenyih by-election on March 2, and she replied: “Not yet … we’ve just talked about it in a general way,”

Source: Bernama

Indonesian salesman in jail for running over policeman at road block

KUALA LUMPUR� An Indonesian salesman was sentenced to five months’ jail by the Ampang Magistrate’s Court here today for voluntarily causing hurt on a traffic policeman last week.

Magistrate Mohamad Firdaus Sadina Ali handed down the sentence on Nasir Saalun, 28, who pleaded guilty to the charge.

He was ordered to serve the jail sentence from the date of arrest, which was last Jan 22.

Source: Bernama

Indonesian salesman in jail for running over policeman at road block

KUALA LUMPUR� An Indonesian salesman was sentenced to five months’ jail by the Ampang Magistrate’s Court here today for voluntarily causing hurt on a traffic policeman last week.

Magistrate Mohamad Firdaus Sadina Ali handed down the sentence on Nasir Saalun, 28, who pleaded guilty to the charge.

He was ordered to serve the jail sentence from the date of arrest, which was last Jan 22.

Source: Bernama